Details of the Drug Reposition

General Information of This Drug (ID: DMBD4K3)

Drug Name
Selinexor   DMBD4K3
Synonyms Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
3 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Multiple myeloma DISEWP9B 2A83 Phase 3 [1]
Liposarcoma DIS8IZVM 2B59 Phase 3 [1]
Neuroendocrine cancer DISVGJET 2B72.1 Phase 3 [1]
------------------------------------------------------------------------------------
5 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Recurrent glioblastoma DISHYPKS 2A00.00 Phase 2 [1]
Solid tumour/cancer DISZR48F 2A00-2F9Z Phase 2 [2]
Acute myeloid leukaemia DIS0BM1I 2A60 Phase 2 [3]
Diffuse large B-cell lymphoma DISSACK3 2A81 Phase 2 [3]
Coronavirus Disease 2019 (COVID-19) DISM7GNX 1D6Y Phase 2 [4]
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT02025985) Phase II Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies. U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 ClinicalTrials.gov (NCT04349098) Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection. U.S. National Institutes of Health.